Allison B Goldfine

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2559811/publications.pdf

Version: 2024-02-01

105 papers	16,686 citations	46918 47 h-index	30848 102 g-index
107 all docs	107 docs citations	107 times ranked	23344 citing authors

#	Article	IF	Citations
1	Inflammation and insulin resistance. Journal of Clinical Investigation, 2006, 116, 1793-1801.	3.9	3,417
2	Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role ofPGC1andNRF1. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8466-8471.	3.3	1,800
3	Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nature Medicine, 2009, 15, 930-939.	15.2	1,790
4	Diabetes primes neutrophils to undergo NETosis, which impairs wound healing. Nature Medicine, 2015, 21, 815-819.	15.2	824
5	Clinical Update: Cardiovascular Disease in Diabetes Mellitus. Circulation, 2016, 133, 2459-2502.	1.6	766
6	Acute Hyperglycemia Attenuates Endothelium-Dependent Vasodilation in Humans In Vivo. Circulation, 1998, 97, 1695-1701.	1.6	743
7	Serum Bile Acids Are Higher in Humans With Prior Gastric Bypass: Potential Contribution to Improved Glucose and Lipid Metabolism. Obesity, 2009, 17, 1671-1677.	1.5	501
8	The Effects of Salsalate on Glycemic Control in Patients With Type 2 Diabetes. Annals of Internal Medicine, 2010, 152, 346.	2.0	343
9	Salsalate Improves Glycemia and Inflammatory Parameters in Obese Young Adults. Diabetes Care, 2008, 31, 289-294.	4.3	322
10	Visceral Adiposity and the Risk of Metabolic Syndrome Across BodyÂMassÂIndex. JACC: Cardiovascular Imaging, 2014, 7, 1221-1235.	2.3	291
11	Ascorbate Restores Endothelium-Dependent Vasodilation Impaired by Acute Hyperglycemia in Humans. Circulation, 2001, 103, 1618-1623.	1.6	290
12	Inhibition of Protein Kinase CÎ² Prevents Impaired Endothelium-Dependent Vasodilation Caused by Hyperglycemia in Humans. Circulation Research, 2002, 90, 107-111.	2.0	278
13	The Cellular Fate of Glucose and Its Relevance in Type 2 Diabetes. Endocrine Reviews, 2004, 25, 807-830.	8.9	273
14	Effects of a Lowâ€“Glycemic Load Diet on Resting Energy Expenditure and Heart Disease Risk Factors During Weight Loss. JAMA - Journal of the American Medical Association, 2004, 292, 2482.	3.8	266
15	Use of Salsalate to Target Inflammation in the Treatment of Insulin Resistance and Type 2 Diabetes. Clinical and Translational Science, 2008, 1, 36-43.	1.5	254
16	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. New England Journal of Medicine, 2020, 382, 2493-2503.	13.9	228
17	Salicylate (Salsalate) in Patients With Type 2 Diabetes. Annals of Internal Medicine, 2013, 159, 1.	2.0	219
18	Roux-en-Y Gastric Bypass Surgery or Lifestyle With Intensive Medical Management in Patients With Type 2 Diabetes. JAMA Surgery, 2014, 149, 716.	2.2	218

#	Article	IF	Citations
19	Activation of Vascular Protein Kinase C-Â Inhibits Akt-Dependent Endothelial Nitric Oxide Synthase Function in Obesity-Associated Insulin Resistance. Diabetes, 2006, 55, 691-698.	0.3	177
20	SerpinB1 Promotes Pancreatic Î² Cell Proliferation. Cell Metabolism, 2016, 23, 194-205.	7.2	177
21	Metabolic effects of vanadyl sulfate in humans with nonâ€"insulin-dependent diabetes mellitus: In vivo and in vitro studies. Metabolism: Clinical and Experimental, 2000, 49, 400-410.	1.5	164
22	Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ: British Medical Journal, 2018, 360, k119.	2.4	132
23	Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. Journal of Clinical Investigation, 2017, 127, 83-93.	3.9	127
24	Defects in muscle branched-chain amino acid oxidation contribute to impaired lipid metabolism. Molecular Metabolism, 2016, 5, 926-936.	3.0	124
25	Serum Ghrelin Levels in Response to Glucose Load in Obese Subjects Postâ€Gastric Bypass Surgery. Obesity, 2003, 11, 919-924.	4.0	113
26	The impact of vitamin D deficiency on diabetes and cardiovascular risk. Current Opinion in Endocrinology, Diabetes and Obesity, 2010, 17, 113-119.	1.2	108
27	Adiponectin: linking the fat cell to insulin sensitivity. Lancet, The, 2003, 362, 1431-1432.	6.3	106
28	Peptide YY Levels Are Elevated After Gastric Bypass Surgery. Obesity, 2006, 14, 194-198.	1.5	104
29	Assessing the Cardiovascular Safety of Diabetes Therapies. New England Journal of Medicine, 2008, 359, 1092-1095.	13.9	102
30	Therapeutic Approaches to Target Inflammation in Type 2 Diabetes. Clinical Chemistry, 2011, 57, 162-167.	1.5	102
31	Clinical and Patient-Centered Outcomes in Obese Patients With Type 2 Diabetes 3 Years After Randomization to Roux-en-Y Gastric Bypass Surgery Versus Intensive Lifestyle Management: The SLIMM-T2D Study. Diabetes Care, 2018, 41, 670-679.	4.3	100
32	Adjustable Gastric Band Surgery or Medical Management in Patients With Type 2 Diabetes: A Randomized Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2546-2556.	1.8	97
33	Increased Glucose Uptake in Visceral Versus Subcutaneous Adipose Tissue Revealed by PET Imaging. JACC: Cardiovascular Imaging, 2010, 3, 843-851.	2.3	91
34	Getting away from glucose: fanning the flames of obesity-induced inflammation. Nature Medicine, 2009, 15, 373-374.	15.2	89
35	Insulin resistance is a poor predictor of type 2 diabetes in individuals with no family history of disease. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2724-2729.	3.3	86
36	Family History of Diabetes Is a Major Determinant of Endothelial Function. Journal of the American College of Cardiology, 2006, 47, 2456-2461.	1.2	83

#	Article	IF	Citations
37	Plasma ceramides are elevated in female children and adolescents with type 2 diabetes. Journal of Pediatric Endocrinology and Metabolism, 2013, 26, 995-8.	0.4	83
38	Dietary Betaine Supplementation Increases Fgf21 Levels to Improve Glucose Homeostasis and Reduce Hepatic Lipid Accumulation in Mice. Diabetes, 2016, 65, 902-912.	0.3	79
39	Statins: Is It Really Time to Reassess Benefits and Risks?. New England Journal of Medicine, 2012, 366, 1752-1755.	13.9	76
40	Continuous Glucose Monitoring for Evaluation of Glycemic Excursions after Gastric Bypass. Journal of Obesity, 2011, 2011, 1-7.	1.1	71
41	Fibrates in the Treatment of Dyslipidemias â€" Time for a Reassessment. New England Journal of Medicine, 2011, 365, 481-484.	13.9	68
42	Effects of Gastric Bypass and Gastric Banding on Bone Remodeling in Obese Patients With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 714-722.	1.8	63
43	Coordination chemistry may explain pharmacokinetics and clinical response of vanadyl sulfate in type 2 diabetic patients. Metallomics, 2013, 5, 1491.	1.0	55
44	Hypoglycemia After Gastric Bypass: The Dark Side of GLP-1. Gastroenterology, 2014, 146, 605-608.	0.6	54
45	Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease. Journal of Diabetes and Its Complications, 2015, 29, 433-437.	1.2	54
46	Insulin response to oral stimuli and glucose effectiveness increased in neuroglycopenia following gastric bypass. Obesity, 2015, 23, 798-807.	1.5	52
47	Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?. Diabetes Care, 2016, 39, 738-742.	4.3	52
48	Effect of Targeting Inflammation With Salsalate. JAMA Cardiology, 2016, 1, 413.	3.0	48
49	Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy. Circulation, 2021, 143, 770-779.	1.6	47
50	Targeting Inflammation Using Salsalate in Patients With Type 2 Diabetes: Effects on Flow-Mediated Dilation (TINSAL-FMD). Diabetes Care, 2013, 36, 4132-4139.	4.3	46
51	Insulin regulates carboxypeptidase E by modulating translation initiation scaffolding protein eIF4G1 in pancreatic Î² cells. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2319-28.	3.3	42
52	Risk of Type 2 Diabetes Is Lower in US Adults Taking Chromium-Containing Supplements. Journal of Nutrition, 2015, 145, 2675-2682.	1.3	41
53	Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway. Current Opinion in Cardiology, 2008, 23, 502-511.	0.8	39
54	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinolâ€"Rationale, Design, and Baseline Data. Diabetes Care, 2019, 42, 1454-1463.	4.3	39

#	Article	IF	Citations
55	Endothelial Function Varies According to Insulin Resistance Disease Type. Diabetes Care, 2007, 30, 1226-1232.	4.3	38
56	TCF7L2 Genetic Variation Augments Incretin Resistance and Influences Response to a Sulfonylurea and Metformin: The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH). Diabetes Care, 2018, 41, 554-561.	4.3	35
57	How common is hypoglycemia after gastric bypass?. Obesity, 2016, 24, 1210-1211.	1.5	33
58	Cardiovascular safety and diabetes drug development. Lancet, The, 2011, 377, 977-979.	6.3	32
59	Plasma FGF-19 Levels are Increased in Patients with Post-Bariatric Hypoglycemia. Obesity Surgery, 2019, 29, 2092-2099.	1.1	32
60	Metabolic Effects of Betaine: A Randomized Clinical Trial of Betaine Supplementation in Prediabetes. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3038-3049.	1.8	30
61	Expansion and contraction: treating diabetes with bariatric surgery. Nature Medicine, 2009, 15, 616-617.	15.2	29
62	LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e57-e70.	1.8	29
63	The Impact of Salsalate Treatment on Serum Levels of Advanced Glycation End Products in Type 2 Diabetes. Diabetes Care, 2014, 37, 1083-1091.	4.3	28
64	Bariatric surgery for diabetes management. Current Opinion in Endocrinology, Diabetes and Obesity, 2009, 16, 119-124.	1.2	25
65	Glucagon Treatment for Postâ€Gastric Bypass Hypoglycemia. Obesity, 2010, 18, 1858-1860.	1.5	23
66	Inhibition of Protein Kinase CÎ² Does Not Improve Endothelial Function in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3783-3787.	1.8	23
67	Molecular determinants of insulin action. Journal of Diabetes and Its Complications, 1993, 7, 92-105.	1.2	22
68	Management of Diabetes Mellitus in Patients With Cardiovascular Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation, 2010, 121, 2447-2449.	1.6	22
69	Design and Clinical Evaluation of a Novel Low-Glucose Prediction Algorithm with Mini-Dose Stable Glucagon Delivery in Post-Bariatric Hypoglycemia. Diabetes Technology and Therapeutics, 2018, 20, 127-139.	2.4	22
70	Hyperinsulinemic hypoglycemia following gastric bypass surgery for obesity. Current Opinion in Endocrinology, Diabetes and Obesity, 2006, 13, 419-424.	0.6	21
71	The Foxo1-Inducible Transcriptional Repressor Zfp125 Causes Hepatic Steatosis and Hypercholesterolemia. Cell Reports, 2018, 22, 523-534.	2.9	21
72	The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH): Design of a pharmacogenetic Resource for Type 2 Diabetes. PLoS ONE, 2015, 10, e0121553.	1.1	20

#	Article	IF	Citations
73	Differential Gene Expression in Diabetic Nephropathy in Individuals With Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E876-E882.	1.8	18
74	Glycemia and Cognitive Function in Metabolic Syndrome and Coronary Heart Disease. American Journal of Medicine, 2015, 128, 46-55.	0.6	18
75	The rollercoaster of post-bariatric hypoglycaemia. Lancet Diabetes and Endocrinology,the, 2016, 4, 94-96.	5.5	18
76	Salsalate improves glycaemia in overweight persons with diabetes risk factors of stable statinâ€treated cardiovascular disease: A 30â€month randomized placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2017, 19, 1458-1462.	2.2	17
77	Physical Activity in Obese Type 2 Diabetes After Gastric Bypass or Medical Management. American Journal of Medicine, 2017, 130, 83-92.	0.6	17
78	Acute Insulin Secretion as a Predictor of Weight Gain in Healthy Humans. Obesity, 2006, 14, 67-72.	1.5	16
79	What Cost Weight Loss?. Circulation, 2012, 125, 1171-1177.	1.6	16
80	Life and Death in Denmark. Circulation, 2008, 117, 1914-1917.	1.6	15
81	Metabolic surgery for type 2 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2013, 20, 98-105.	1.2	15
82	Adjustable gastric band surgery or medical management in patientsÂwith type 2 diabetes and obesity: three-year results ofÂaÂrandomized trial. Surgery for Obesity and Related Diseases, 2019, 15, 2052-2059.	1.0	14
83	Cardiovascular Risk Assessment in the Development of New Drugs for Obesity. JAMA - Journal of the American Medical Association, 2012, 308, 1099.	3.8	13
84	Diabetes Improvement Following Roux-en-Y Gastric Bypass: Understanding Dynamic Changes in Insulin Secretion and Action. Diabetes, 2014, 63, 1454-1456.	0.3	13
85	Heterogeneity of proliferative markers in pancreatic Î²-cells of patients with severe hypoglycemia following Roux-en-Y gastric bypass. Acta Diabetologica, 2017, 54, 737-747.	1.2	13
86	High-throughput mediation analysis of human proteome and metabolome identifies mediators of post-bariatric surgical diabetes control. Nature Communications, 2021, 12, 6951.	5.8	13
87	PET-CT reveals increased intestinal glucose uptake after gastric surgery. Surgery for Obesity and Related Diseases, 2019, 15, 643-649.	1.0	10
88	Insulin regulates arginine-stimulated insulin secretion in humans. Metabolism: Clinical and Experimental, 2022, 128, 155117.	1.5	9
89	Impact of Acipimox Therapy on Free Fatty Acid Efflux and Endothelial Function in the Metabolic Syndrome: A Randomized Trial. Obesity, 2019, 27, 1812-1819.	1.5	7
90	Type 2 Diabetes: New Drugs, New Perspectives. Hospital Practice (1995), 2001, 36, 29-36.	0.5	5

#	Article	IF	Citations
91	The rough road for rosiglitazone. Current Opinion in Endocrinology, Diabetes and Obesity, 2008, 15, 113-117.	1.2	5
92	Response to Brosch etÂal.. Cell Metabolism, 2012, 15, 267-269.	7.2	5
93	Where Are the Health Care Cost Savings With Bariatric Surgery in Obesity Management?. JAMA Surgery, 2014, 149, 5.	2.2	5
94	Bariatric surgery for T2DMâ€"cure, or remission and relapse?. Nature Reviews Endocrinology, 2014, 10, 8-9.	4.3	5
95	Effects of the anti-inflammatory drug salsalate on bone turnover in type 2 diabetes mellitus. Endocrine, 2015, 50, 504-507.	1.1	5
96	The role of HDL- and non-HDL-related parameters in cell-cholesterol efflux capacity. Atherosclerosis, 2022, 345, 1-6.	0.4	4
97	Pramlintide for <scp>postâ€bariatric</scp> hypoglycaemia. Diabetes, Obesity and Metabolism, 2022, 24, 1021-1028.	2.2	4
98	Response to Comment on Goldfine et al. Targeting Inflammation Using Salsalate in Patients With Type 2 Diabetes: Effects on Flow-Mediated Dilation (TINSAL-FMD). Diabetes Care 2013;36:4132â€"4139. Diabetes Care, 2014, 37, e112-e112.	4.3	2
99	Changing horizons: approaches to diabetes care, current and future. Current Opinion in Endocrinology, Diabetes and Obesity, 2007, 14, 95-97.	1.2	1
100	305: Response to Colesevelam HCl in Patients with Type 2 Diabetes. Journal of Clinical Lipidology, 2008, 2, 229.	0.6	1
101	New lessons from gastric bypass: Impact of glucoseâ€independent islet function. Obesity, 2015, 23, 1942-1943.	1.5	1
102	Beyond the scale: understanding mechanisms of weight gain and obesity in diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2005, 12, 143-145.	0.6	0
103	Severe hypoglycemia postgastric bypass requiring partial pancreatectomy: Evidence for inappropriate insulin secretion and pancreatic islet hypertrophy. Surgery for Obesity and Related Diseases, 2005, 1, 278-279.	1.0	0
104	Diabetes and cardiovascular disease: does sugar matter?. Current Opinion in Endocrinology, Diabetes and Obesity, 2006, 13, 99-102.	0.6	0
105	300: The Use of Colesevelam HCl with Concomitant Statin Therapy in Type 2 Diabetes Mellitus Improves Glycemic Control and the Lipid Profile. Journal of Clinical Lipidology, 2008, 2, 226.	0.6	0